Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host an investor event and live webcast to discuss the ETC-1002 development program, including the Phase 2b ETC-1002-008 results announced last month.
Help employers find you! Check out all the jobs and post your resume.
